Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features - Wikidata - awgldk - TriplyDB

Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features

Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features

http://www.wikidata.org/entity/Q35840816

about

Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria.Functional autoantibodies in systemic sclerosis pathogenesis.Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF).[The German network for systemic sclerosis (DNSS): current data on diagnostics and therapy].Clinical and autoimmune profile of scleroderma patients from Western India.Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases: It is all about the patient!Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis.Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma.Antinuclear antibody-negative systemic sclerosis.Aldolase predicts subsequent myopathy occurrence in systemic sclerosis Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis.Case 3: - congestive heart failure in male with systemic sclerosis.Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma.Molecular and cellular basis of scleroderma.The Clinical Relevance of Antifibrillarin (anti-U3-RNP) Autoantibodies in Systemic Sclerosis.Recent advances in managing systemic sclerosis.Clinical and serological associations of autoantibodies to the Ku70/Ku80 heterodimer determined by a novel chemiluminescent immunoassay.Innate Immunity in Systemic Sclerosis.Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies.The utility of comprehensive autoantibody testing to differentiate connective tissue disease associated and idiopathic interstitial lung disease subgroup cases.Incidence and prevalence of systemic sclerosis in Campo Grande, State of Mato Grosso do Sul, Brazil.Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort.Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais.Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects.Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis.Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing.Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay.Health-care utilization in Dutch systemic sclerosis patients.[Systemic scleroderma].Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis.The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodies.[Common German language nomenclature for systemic sclerosis].European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients.Common and specific associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies in systemic lupus erythematosus

P2860

Q26995764-192AB650-DB55-4904-B35F-A1809A25123F Q27000819-0C5A7A2E-540B-4361-A695-C767A218AC05 Q30658087-A3A112C7-3663-4EBE-86C1-9DE7B097AEDF Q33360501-DFCA803C-923D-49A9-A916-A548C2764874 Q33737250-9E8828DC-2DFC-44D4-9E82-A24D19E36349 Q34250693-762058CE-D6B2-467F-A0FE-618D428878C3 Q34438113-B7B567F0-97CE-4BE9-ADDF-26B28BEB4603 Q35309739-66953E6E-4898-487D-8B5B-CEA53CA20CC9 Q35352582-8256B0A4-C198-4D28-B49B-FD49F8766648 Q35532333-D5888AEF-023F-42EC-88FB-4B75D0472982 Q35661256-AFCA17C6-FD00-422C-BBA1-5F38076FB689 Q36246152-9704B535-F2E8-4AA1-9478-DFDA1F26C6AE Q36709262-8214A6C3-8F39-4068-824B-69577F4C49C5 Q37720766-48023CC5-7C62-4F5D-B81E-59AA30E7B4BE Q38019862-2A7BB614-FE16-478D-B162-49FA91F14459 Q38230276-6DA0DECE-7FCE-49F2-851C-AC9827813F67 Q38730172-723352E0-4A8E-4CAB-A6DC-FC9B97EEA70A Q38759138-13C718A8-ABFF-4535-BD18-1D903DE0BB5B Q38851103-AEBA6F2D-E3EE-4624-8812-45B35C6504FD Q39100157-6A7A6FD0-BEF9-48C0-AB32-A2CC4549A3F0 Q39111684-1EF60354-C64A-429D-B360-82382B6DFDDA Q39198820-4971A274-46A0-4866-AD62-2414798C6202 Q39332233-93E07057-6BBE-49B6-A4F2-321DA485F7E6 Q40176801-12295597-66BF-4DB7-A0D0-3DF949BE4242 Q40291320-68EA987D-6C1A-425D-AC02-EAA9418DBC04 Q40491053-F1C36EAF-BA4E-4388-B668-ABB6F9A54891 Q40579823-9F4EF83B-430B-4FC2-AEA7-485B427B899F Q40656308-B97CFAE6-71F7-4F9C-A441-93B556F77074 Q41187671-9C561A5D-3F89-488C-8FFD-76362E64F3CB Q41197918-0229B681-C772-485B-9278-3D346FB26407 Q41532980-8A750DFF-44BD-4935-9B8C-277E63DA887E Q44846676-A8DEF7E4-F6D9-457B-94DC-B5F52A7B54F5 Q45203681-F484D266-2331-44EE-8C57-31BAD068BE9E Q47238136-57B832B3-B248-4ADA-AA3D-44E8C869D6D7 Q48566617-3E374DD2-089A-41E4-B932-F6542CFE1B80 Q48588423-B7C9CCE2-4827-44D4-9D8A-C1C06CB855E2 Q49072027-0C94ECF2-112C-473B-B02E-FE47B649099C Q52597638-F5A13B12-83EA-41E6-BC14-0BBD49CE8BC1 Q54374398-8A093B24-F674-462C-B4B1-301744117B25 Q59034615-E3C4DF4C-E4A0-4D81-A603-439B5E82A66C

P2860

Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features

http://www.wikidata.org/entity/Q35840816

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Frequency of disease-associate ...... aracteristic clinical features

@ast

Frequency of disease-associate ...... aracteristic clinical features

@en

type

label

Frequency of disease-associate ...... aracteristic clinical features

@ast

Frequency of disease-associate ...... aracteristic clinical features

@en

prefLabel

Frequency of disease-associate ...... aracteristic clinical features

@ast

Frequency of disease-associate ...... aracteristic clinical features

@en

P1433

Q35840816-145A3FF8-5701-4E02-A972-485F73C30E5B

P1476

Q35840816-23427704-09A1-4AA1-B7EF-03C78B16DA00

P2093

Q35840816-08A374E8-0341-4876-9030-3BE1D4ABE52A

Q35840816-11F7FBF4-E4D8-4DBA-BAA7-62F7427AD161

Q35840816-1CDE4D3D-50E0-45AB-BB05-271E3FE5D865

Q35840816-1DBAB21E-FB99-4A80-8A6D-871D28172405

Q35840816-33A6C546-71A2-4EB5-9BB3-5D472D6F6DE7

Q35840816-43E941C8-2F9A-4F68-96AA-ED8937B9BE01

Q35840816-4E7FB71F-2798-43F3-8D90-70547C10DCC6

Q35840816-9E476918-9637-4CCF-98E5-F2BD3D755979

Q35840816-A7548BEF-29A7-4038-B683-353BEA1F05DD

Q35840816-AFA6FB8C-1A33-4B6C-949B-108B31D7DCEF

P2860

Q35840816-00187F7C-E0E2-4B67-87DD-7D2ACE2EBE1F

Q35840816-039F5148-3D2B-44D5-BF49-77E37468D415

Q35840816-0CDB6CBD-6704-4016-8660-11684B8F7228

Q35840816-0EA722F8-351A-4DB3-9839-C4C40BC0E669

Q35840816-0EB7D55B-4377-40B4-AE96-4247A1432402

Q35840816-10399BD4-7B35-44E3-8F3B-76DF571692CF

Q35840816-17B2A5B6-CC41-4534-9459-A9449E8ACCC5

Q35840816-1B01C267-58CE-4511-BBEE-E4359F7DDC6D

Q35840816-236F331F-9BFC-4E62-80CB-6471A55F245A

Q35840816-24638A4D-3E4C-4444-9693-B1D24BC746A1

P2888

Q35840816-8A775662-CCC5-498F-94E9-51D81E75DA6A

P304

Q35840816-7A110D55-1436-43B8-B170-EA86D7BA0240

P31

Q35840816-30F7B6D3-E45B-4AF9-8F61-67207CD8C0AA

P356

Q35840816-094723FA-BD82-49E4-837C-884D33205F24

P433

Q35840816-A3AED7D9-13B6-4ADD-83B4-F6F7ADBBBD51

P478

Q35840816-981DE3B8-5EE9-412F-BF5C-1252290D803B

P50

Q35840816-37C5FA52-E1DA-43A2-8B6F-8C220C4771D8

Q35840816-66A3E124-9E7A-4B3E-9191-62D472A03207

Q35840816-754B0DAA-214B-4F8F-849A-508742EF93A7

Q35840816-9C6D3160-7504-4160-ADA9-CCAA1486D749

Q35840816-A24F176E-F701-4DDD-965F-EAC2887D991D

P577

Q35840816-776FB711-C96F-4BC3-96A1-0E99A7C383AF

P5875

Q35840816-BE5D3DC3-FEC9-4E90-BFEC-9E12058AEDE5

P6179

Q35840816-487C07C6-682A-4FA9-885D-4A274E5BBFC2

P698

Q35840816-5DAA9875-2907-4B34-AE24-B93C5C464C1B

P921

Q35840816-3C1236E1-15EF-4411-9E79-B31F565381FC

P932

Q35840816-DDBE0DCE-62EA-4DF0-88B9-2E7D3B8556F2

P356

P1433

Arthritis Research and Therapy

P1476

Frequency of disease-associate ...... aracteristic clinical features

@en

P2093

Aaron Juche

http://www.w3.org/2001/XMLSchema#string

Annegret Kuhn

http://www.w3.org/2001/XMLSchema#string

Christiane Pfeiffer

http://www.w3.org/2001/XMLSchema#string

Christoph Fiehn

http://www.w3.org/2001/XMLSchema#string

Cord Sunderkötter

http://www.w3.org/2001/XMLSchema#string

Cornelia Seitz

http://www.w3.org/2001/XMLSchema#string

Eckhard Schulze-Lohoff

http://www.w3.org/2001/XMLSchema#string

Ekkehard Genth

http://www.w3.org/2001/XMLSchema#string

Frank Reichenberger

http://www.w3.org/2001/XMLSchema#string

Inga Melchers

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis

Heterochromatin protein HP1Hsbeta (p25beta) and its localization with centromeres in mitosis

Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen

Scleroderma overlap syndromes

Undifferentiated connective tissue syndromes

Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA.

Clinical features of anti-chromo antibodies associated with anti-centromere antibodies.

Epitope analysis of chromo antigen and clinical features in a subset of patients with anti-centromere antibodies.

Autoantibody detection using indirect immunofluorescence on HEp-2 cells.

Frequency and clinical associations of anti-chromo antibodies in connective tissue disease.

P2888

P304

R172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR3495

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Gabriela Riemekasten

Ulf Müller-Ladner

Eckhard Schulze-Lohoff

Cord Sunderkötter

P577

2011-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51740673

http://www.w3.org/2001/XMLSchema#string

P6179

1001755554

http://www.w3.org/2001/XMLSchema#string

P698

22018289

http://www.w3.org/2001/XMLSchema#string

P921

P932

3308107

http://www.w3.org/2001/XMLSchema#string